Pfizer posts 30% rise in quarterly profit

[July 29, 2019]  (Reuters) - Pfizer Inc <PFE.N> on Monday reported a 30% rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz.

 The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly

Pfizer, which was scheduled to report its second-quarter earnings on Tuesday, also said it would combine Upjohn, its off-patent drugs business, with Mylan NV <MYL.O>.

Pfizer said net income rose to $5.05 billion, or 89 cents per share, in the second quarter, from $3.87 billion, or 65 cents per share, a year earlier.

Revenue fell 1.5% to $13.26 billion.

(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

[© 2019 Thomson Reuters. All rights reserved.]

Copyright 2019 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.